EICHOR
● Active Not Recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Condition: Solid Tumors · Gastric Cancer · Non-Small Cell Lung Cancer (NSCLC) · Sponsor: EMD Serono Research & Development Institute, Inc.
About this study
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (81)
| University of California - Los Angeles - 300208353 | Santa Monica, California, United States | — |
| Providence Medical Foundation | Santa Rosa, California, United States | — |
| Georgetown University - Lombardi Comprehensive Cancer Center - 1134847 | Washington D.C., District of Columbia, United States | — |
| D&H Cancer Research Center | Margate, Florida, United States | — |
| Prisma Health Cancer Institute, ITOR, CRU | Greenville, South Carolina, United States | — |
| Baptist Cancer Center | Memphis, Tennessee, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| NEXT Virginia | Fairfax, Virginia, United States | — |
| Flinders Medical Centre | Bedford Park, Australia | — |
| Nepean Cancer Care Centre | Kingswood, Australia | — |
| Mater Misericordiae Ltd - PARENT | South Brisbane, Australia | — |
| Macquarie University Hospital - PARENT | Sydney, Australia | — |
+ 69 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06710132